Cash/Burn From SEC Filing For Period: 

Q1 '20

HRTX

Heron Therapeutics

For AMP's current thesis as well as the bull and bear thesis on HRTX go here: https://bit.ly/3dT4xyo

At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.

Cash

$356.3M

Burn Rate

-$51.6M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Sustol

Nausea Associated With Chemo

Quarterly Sales (Approved)

August 5, 2020 (Est)

Cinvanti

Nausea Associated With Chemo

Quarterly sales (approved)

August 5, 2020 (Est)

HTX-011

Postoperative pain

Report out on post-CRL FDA meeting

August 5, 2020 (Est)

HTX-034

Post operative pain

Pre-Clinical

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

HRTX CRL for HTX-011...

Heron Therapeutics received a Complete Response Letter from the U.S. FDA for the NDA for HTX-011 which is used for post-operative pain. The FDA stated that the CRL was given out because of a need for ...

HRTX - bear or bull? Our take ...

Heron has an upcoming PDUFA date for its longer acting post-op pain medicine, HTX-011. This is the second time around for HTX-011 as the first time unfortunately resulted in a CRL. See our article (HE...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon